JB Pharma’s Q2 results propel stock to 52-week high; Should you buy, hold or sell the stock-

JB Chemicals &Pharmaceuticals’ shares soared over 5% to hit a fresh 52-week high of Rs 1,536.25 a day after the company posted a 36% surge in profit after tax at Rs 151 crore in the second quarter of FY25 compared to Rs 111 crore in Q2FY23. The company’s revenue in the quarter under review stood at Rs 882 crore, as against Rs 809 crore in the corresponding period a year ago, JB Chemicals & Pharmaceuticals said in a statement.

JB Chemicals & Pharmaceuticals have been on a winning streak, treating investors with impressive returns over the last one year. The share price has gained 8.29% in the last five days, 3.55% in the last one month, 47.50% in the last six months and a whopping 55.18% year to date. 

Also Read

Alkem Laboratories posts buoyant growth in Q2; Should you buy, hold or sell the stock?

Should you buy, sell or hold JB Pharma’s shares?

Jefferies: Buy – Target Price: 1680

“JB Pharma’s 2QFY24 EBITDA was 8% above estimates despite 2% revenue miss due to superior gross margins and lower opex. India sales grew 11% YoY led by 18% YoY growth in chronic sales (52% of India sales). Strong India and CDMO outlook coupled with gradual margin improvement from improving chronic mix and field force productivity keep us positive. We raise FY24-26E EPS by 4-7% and Target Price to Rs 1,680 from Rs 1,555. Maintain ‘Buy’.”

Market rally leads to higher regulatory fees for stock exchanges Multibagger SJVN jumps 8% after Q1 net profit zooms 31% RBI likely to maintain status quo, unlikely to cut rates before September Indexed ad volumes per Channel on TV dropped 3% in H1,2024 compared to the same period of previous year, reveals TAM report 

Prabhudas Lilladher: Buy – Target Price : Rs 1675

“We believe JB Chemicals & Pharmaceuticals will continue with its growth momentum driven by 1) geographical expansion of legacy brands 2) improvement in MR productivity 3) scale up in Sanzyme, Azmarda and Razel franchise 4) launch of new products & therapies 5) scaling up contract manufacturing business and 6) improvement in FCF generation. Our FY24/25E EPS stands broadly remains unchanged. We expect EPS CAGR of 29% over FY23-26E. At CMP, the stock is trading at 27x FY25E P/E adjusted for ESOP and amortization charges. We maintain our ‘BUY’ rating with revised Target Price of Rs 1,675/share (Rs 1,500 earlier), valuing at 30x Sept 2025E EPS adjusted for ESOP and amortization charges.”

(The recommendations in this story are by the respective research analysts and brokerage firms. FinancialExpress.com does not bear any responsibility for their investment advice Come from Sports betting site VPbet . Capital markets investments are subject to rules and regulations. Please consult your investment advisor before investing.)

Related Posts

เกมมือถือใหม่ล่าสุด TSX by Astronize เปิดดาวน์โหลดแล้ววันนี้!

TSX by Astronize เกมมือถือ Play & Earn แนว Turn-based RPG อัปเกรดจากจักรวาล TS Online Mobile สุดคลาสสิก เปิดให้ดาวน์โหลดแล้ววันนี้เพื่อเตรียมพร้อมมันส์ในจักรวาลต่างมิติ�…

Read more